DuPont Pharmaceuticals Names Tim Ravenscroft Senior Vice President Of Virology Franchise

Apr 04, 2001, 01:00 ET from DuPont Pharmaceuticals Company

    WILMINGTON, Del., April 4 /PRNewswire/ -- DuPont Pharmaceuticals Company
 today announced Tim Ravenscroft has been named Senior Vice President,
 Virology.  In this role, he will be responsible for the company's global
 Virology commercial strategy as well as serve as the leader of the Virology
 sales and marketing teams in the United States.  Ravenscroft will also manage
 the worldwide introduction of second-generation anti-HIV compounds currently
 being developed in all three classes of antiretrovirals.
     Ravenscroft was most recently Vice President of Business Development and
 Strategic Planning, responsible for global commercial development and business
 strategy for the virology, anti-inflammatory and central nervous system
 disease areas.  Prior to this position, Ravenscroft was Vice President,
 European Virology where he was responsible for the launch of Sustiva(TM)
 (efavirenz).
     Before joining DuPont Pharmaceuticals in 1997, Ravenscroft was director of
 HIV Portfolio Global Development for Glaxo Wellcome and worked in various
 therapeutic areas including neurology, cardiology and respiratory.
     "Tim has tremendous worldwide experience in the development and marketing
 of virology products," said Joseph C. Papa, President and Chief Operating
 Officer, DuPont Pharmaceuticals.  "In his new role, Tim will be responsible
 for commercializing DuPont Pharmaceuticals' new life saving HIV therapies."
     Ravenscroft earned a bachelor's degree of science in
 biochemistry/microbiology from North East London University and a master's
 degree of science in information science from City University in London.
     DuPont Pharmaceuticals Company, a wholly owned subsidiary of DuPont, is a
 worldwide business focused on research, development and delivery of
 pharmaceuticals and imaging agents to treat unmet medical needs in the fights
 against HIV/AIDS, cardiovascular disease, inflammatory diseases, cancer and
 neurological diseases.
     DuPont (NYSE:   DD) is a science company, delivering science-based solutions
 that make a difference in people's lives in food and nutrition; health care;
 apparel; home and construction; electronics; and transportation.  Founded in
 1802, the company operates in 70 countries and has 93,000 employees.
 
     Sustiva(TM) is a trademark of DuPont Pharmaceuticals Company.
 
 

SOURCE DuPont Pharmaceuticals Company
    WILMINGTON, Del., April 4 /PRNewswire/ -- DuPont Pharmaceuticals Company
 today announced Tim Ravenscroft has been named Senior Vice President,
 Virology.  In this role, he will be responsible for the company's global
 Virology commercial strategy as well as serve as the leader of the Virology
 sales and marketing teams in the United States.  Ravenscroft will also manage
 the worldwide introduction of second-generation anti-HIV compounds currently
 being developed in all three classes of antiretrovirals.
     Ravenscroft was most recently Vice President of Business Development and
 Strategic Planning, responsible for global commercial development and business
 strategy for the virology, anti-inflammatory and central nervous system
 disease areas.  Prior to this position, Ravenscroft was Vice President,
 European Virology where he was responsible for the launch of Sustiva(TM)
 (efavirenz).
     Before joining DuPont Pharmaceuticals in 1997, Ravenscroft was director of
 HIV Portfolio Global Development for Glaxo Wellcome and worked in various
 therapeutic areas including neurology, cardiology and respiratory.
     "Tim has tremendous worldwide experience in the development and marketing
 of virology products," said Joseph C. Papa, President and Chief Operating
 Officer, DuPont Pharmaceuticals.  "In his new role, Tim will be responsible
 for commercializing DuPont Pharmaceuticals' new life saving HIV therapies."
     Ravenscroft earned a bachelor's degree of science in
 biochemistry/microbiology from North East London University and a master's
 degree of science in information science from City University in London.
     DuPont Pharmaceuticals Company, a wholly owned subsidiary of DuPont, is a
 worldwide business focused on research, development and delivery of
 pharmaceuticals and imaging agents to treat unmet medical needs in the fights
 against HIV/AIDS, cardiovascular disease, inflammatory diseases, cancer and
 neurological diseases.
     DuPont (NYSE:   DD) is a science company, delivering science-based solutions
 that make a difference in people's lives in food and nutrition; health care;
 apparel; home and construction; electronics; and transportation.  Founded in
 1802, the company operates in 70 countries and has 93,000 employees.
 
     Sustiva(TM) is a trademark of DuPont Pharmaceuticals Company.
 
 SOURCE  DuPont Pharmaceuticals Company